Plain-English translation of NCT07424547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of cancer drug called an antibody-drug conjugate, which is designed to find and destroy cancer cells. The study is enrolling people with advanced or metastatic solid tumors—including lung, breast, ovarian, and prostate cancers—to see whether this medication is safe and how well it works. The trial has three phases, starting with small doses to find the safest effective dose, then expanding to test that dose in larger groups of patients.
Currently, many patients with advanced cancers have limited treatment options when standard therapies stop working or are not suitable for them. This medication targets a protein called B7-H3 that is often found on cancer cells, offering a potentially new way to treat these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You would start with the first phase of the trial, where you would receive increasing doses of the medication to determine the safest and most effective dose. Depending on how you respond, you may continue in the second phase, where the dose is kept steady while doctors monitor your safety and how the cancer responds. Throughout the trial, you would have regular clinic visits for blood tests, heart monitoring, imaging scans, and check-ins with the research team. The trial is designed to help doctors understand whether this new medication is safe and whether it helps shrink or slow down your cancer.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States